Adocia SA (ADOC.PA)
EUR 6.39
(1.59%)
EUR 6.39
(1.59%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 24.95 Million EUR | -18.48% |
| 2022 | 30.61 Million EUR | 1.86% |
| 2021 | 30.05 Million EUR | -33.46% |
| 2020 | 45.16 Million EUR | -27.1% |
| 2019 | 61.95 Million EUR | -11.55% |
| 2018 | 70.04 Million EUR | 30.29% |
| 2017 | 53.76 Million EUR | -31.77% |
| 2016 | 78.79 Million EUR | -10.55% |
| 2015 | 88.09 Million EUR | 67.66% |
| 2014 | 52.54 Million EUR | 112.48% |
| 2013 | 24.72 Million EUR | -32.48% |
| 2012 | 36.62 Million EUR | 107.68% |
| 2011 | 17.63 Million EUR | 17.08% |
| 2010 | 15.06 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 23.65 Million EUR | 0.0% |
| 2023 Q3 | 24.95 Million EUR | 18.84% |
| 2023 Q4 | 24.95 Million EUR | 0.0% |
| 2023 Q1 | 21 Million EUR | -31.4% |
| 2023 FY | 24.95 Million EUR | -18.48% |
| 2023 Q2 | 21 Million EUR | 0.0% |
| 2022 FY | 30.61 Million EUR | 1.86% |
| 2022 Q3 | 30.61 Million EUR | -26.76% |
| 2022 Q4 | 30.61 Million EUR | 0.0% |
| 2022 Q2 | 41.79 Million EUR | 0.0% |
| 2022 Q1 | 41.79 Million EUR | 39.08% |
| 2021 Q3 | 30.05 Million EUR | -11.04% |
| 2021 Q4 | 30.05 Million EUR | 0.0% |
| 2021 Q1 | 33.78 Million EUR | -25.2% |
| 2021 FY | 30.05 Million EUR | -33.46% |
| 2021 Q2 | 33.78 Million EUR | 0.0% |
| 2020 Q2 | 50.05 Million EUR | 0.0% |
| 2020 Q1 | 50.05 Million EUR | -19.2% |
| 2020 Q3 | 45.16 Million EUR | -9.77% |
| 2020 Q4 | 45.16 Million EUR | 0.0% |
| 2020 FY | 45.16 Million EUR | -27.1% |
| 2019 Q2 | 55.7 Million EUR | -0.0% |
| 2019 Q4 | 61.95 Million EUR | 0.0% |
| 2019 FY | 61.95 Million EUR | -11.55% |
| 2019 Q1 | 55.7 Million EUR | -20.47% |
| 2019 Q3 | 61.95 Million EUR | 11.22% |
| 2018 Q3 | 70.04 Million EUR | -14.47% |
| 2018 FY | 70.04 Million EUR | 30.29% |
| 2018 Q4 | 70.04 Million EUR | 0.0% |
| 2018 Q2 | 81.89 Million EUR | 0.0% |
| 2018 Q1 | 81.88 Million EUR | 52.32% |
| 2017 Q1 | 68.41 Million EUR | -13.18% |
| 2017 Q2 | 68.41 Million EUR | 0.0% |
| 2017 Q3 | 53.76 Million EUR | -21.42% |
| 2017 Q4 | 53.76 Million EUR | 0.0% |
| 2017 FY | 53.76 Million EUR | -31.77% |
| 2016 Q2 | 86.66 Million EUR | 0.0% |
| 2016 FY | 78.79 Million EUR | -10.55% |
| 2016 Q1 | 86.66 Million EUR | -1.62% |
| 2016 Q3 | 78.79 Million EUR | -9.08% |
| 2016 Q4 | 78.79 Million EUR | 0.0% |
| 2015 Q3 | 88.09 Million EUR | 7.11% |
| 2015 Q2 | 82.25 Million EUR | 0.0% |
| 2015 FY | 88.09 Million EUR | 67.66% |
| 2015 Q1 | 82.25 Million EUR | 56.54% |
| 2015 Q4 | 88.09 Million EUR | 0.0% |
| 2014 Q2 | 19.84 Million EUR | 0.0% |
| 2014 Q3 | 52.54 Million EUR | 164.77% |
| 2014 Q4 | 52.54 Million EUR | 0.0% |
| 2014 Q1 | 19.84 Million EUR | -19.75% |
| 2014 FY | 52.54 Million EUR | 112.48% |
| 2013 Q1 | 30.37 Million EUR | -17.06% |
| 2013 Q4 | 24.72 Million EUR | 0.0% |
| 2013 Q2 | 30.37 Million EUR | 0.0% |
| 2013 Q3 | 24.72 Million EUR | -18.59% |
| 2013 FY | 24.72 Million EUR | -32.48% |
| 2012 Q3 | 36.62 Million EUR | -9.13% |
| 2012 Q4 | 36.62 Million EUR | 0.0% |
| 2012 FY | 36.62 Million EUR | 107.68% |
| 2012 Q2 | 40.3 Million EUR | 0.0% |
| 2011 FY | 17.63 Million EUR | 17.08% |
| 2011 Q4 | 17.63 Million EUR | 0.0% |
| 2010 FY | 15.06 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -69.653% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 92.37% |
| Aelis Farma SA | 26.28 Million EUR | 5.042% |
| Biophytis S.A. | 11.93 Million EUR | -109.082% |
| Advicenne S.A. | 12.4 Million EUR | -101.145% |
| genOway Société anonyme | 31.84 Million EUR | 21.626% |
| IntegraGen SA | 8 Million EUR | -211.936% |
| Medesis Pharma S.A. | 1.92 Million EUR | -1195.517% |
| Neovacs S.A. | 47.53 Million EUR | 47.498% |
| NFL Biosciences SA | 3.97 Million EUR | -528.515% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -67.345% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -566.067% |
| Sensorion SA | 46.49 Million EUR | 46.324% |
| Theranexus Société Anonyme | 7.23 Million EUR | -244.804% |
| TME Pharma N.V. | 2.49 Million EUR | -901.847% |
| Valbiotis SA | 33.24 Million EUR | 24.94% |
| TheraVet SA | 7.53 Million EUR | -231.237% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 29.251% |
| argenx SE | 4.11 Billion EUR | 99.393% |
| BioSenic S.A. | 9.55 Million EUR | -161.073% |
| Celyad Oncology SA | 16.28 Million EUR | -53.274% |
| DBV Technologies S.A. | 165.65 Million USD | 84.935% |
| Galapagos NV | 4.35 Billion EUR | 99.427% |
| Genfit S.A. | 173.87 Million EUR | 85.647% |
| GeNeuro SA | 6.31 Million EUR | -295.318% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 47.66% |
| Innate Pharma S.A. | 184.19 Million EUR | 86.451% |
| Inventiva S.A. | 69.13 Million EUR | 63.905% |
| MaaT Pharma SA | 42.93 Million EUR | 41.87% |
| MedinCell S.A. | 36.94 Million EUR | 32.456% |
| Nanobiotix S.A. | 93.89 Million EUR | 73.422% |
| Onward Medical N.V. | 43.62 Million EUR | 42.8% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 76.655% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 69.529% |
| Oxurion NV | 6.55 Million EUR | -281.008% |
| Pharming Group N.V. | 426.33 Million EUR | 94.146% |
| Poxel S.A. | 4.82 Million EUR | -417.437% |
| GenSight Biologics S.A. | 9.08 Million EUR | -174.634% |
| Transgene SA | 45.21 Million EUR | 44.808% |
| Financière de Tubize SA | 1.92 Billion EUR | 98.7% |
| UCB SA | 15.53 Billion EUR | 99.839% |
| Valneva SE | 469.39 Million EUR | 94.683% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | 19.05% |